Lagis Enterprise Co (6730) Fair Value & Analysis
Healthcare · TW · Market cap 1.3B TWD
Fair value as of: Jul 21, 2026
From 26 valuation models · updated 20 days ago
Share price −8.2% over the past month.
Below-average quality, and screening another 39% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (33.70 TWD). The favourable scenario is already priced in.
- Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (15.06 TWD to 33.70 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 25.48 TWD – 48.20 TWD · fair‑value band 15.06 TWD – 33.70 TWD · the 34.50 TWD price screens above the 21.00 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Lagis Enterprise Co (6730) currently trades at 34.50 TWD, while our model-based Fair Value estimate is 21.00 TWD, implying the stock looks roughly 39.1% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Lagis Enterprise Co generated revenue of 487M TWD at a net margin of 13.9%. Revenue declined 1.0% year over year. It earns a return on equity of 10.5%. Net debt stands at 172M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 15.06 TWD (bear case) to 33.70 TWD (bull case); at 34.50 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -39%, 6730 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (33.35 TWD) versus Growth DCF (9.57 TWD). Highest evidence: Growth DCF (80).
Notify me when 6730 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Lagis Enterprise Co., Ltd. engages in the manufacturing, processing, and sale of surgical instruments, equipment, and related medical devices Taiwan and China.
Full company description
Lagis Enterprise Co., Ltd. engages in the manufacturing, processing, and sale of surgical instruments, equipment, and related medical devices Taiwan and China. Its products include trocars, include optical tip trocar, dilating tip trocar, shielded bladed tip trocar, blunt tip trocar, TRE trocar system, balloon trocar; single port surgery devices, include advanced single port device, single port kit for TAMIS, and advanced single port device for vNOTES; path cap and shield wound reactors; energy bipolar forceps; suction irrigation systems and irrigation pumps; electrosurgery system; endo endoscopic instruments, include scissors and dissectors, graspers, mini laparoscopy grasping device, and laparoscopic electrode; and retrieval specimen bags. The company sells its products under LAGIS brand name. Lagis Enterprise Co., Ltd. was founded in 2004 and is headquartered in Taichung, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lagis Enterprise Co reported revenue of 488M TWD in FY2025 versus 393M TWD in FY2021, a compound +5.5%/yr. Reported net income was 69.3M TWD in FY2025, compounding +9.1%/yr from FY2021.
6730 screens 39% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Lagis Enterprise Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lagis Enterprise Co (6730) overvalued or undervalued?
What is the fair value of 6730?
What is the quality score of 6730?
What is the revenue of Lagis Enterprise Co (6730)?
What is the net profit margin of 6730?
Does Lagis Enterprise Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Lagis Enterprise Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.